Nifedipine

An important property of the calcium antagonists is their differing tissue selectivity. For example, whereas verapamil for all practical purposes is equi-effective with respect to the myocardium, vasculature, conducting and nodal tissue, making it a broad spectrum calcium antagonist so far as the cardiovascular system is concerned Table 2 ; , nifedipine has no direct effect on the conducting and nodal tissues at concentrations which render it more effective as a vasodilator than either verapamil or diltiazem Table 2 ; . Unfortunately nifedipine retains an effect on the myocardium, although certainly the ratio between its effect on the vasculature relative to that on the myocardium favours the vascular effect Table 2 ; . Nifedipnie was quickly followed by a plethora of other dihydropyridine-based antagonists, developed because of their enhanced selectivity for the vasculature relative to the myocardium, whilst having no direct clinically relevant effect on either nodal or conducting tissues. Some of these more recently developed dihydropyridine-based antagonists have pharmacological profiles which render them potentially useful for the management of problems within specific vascular beds. Nimodipine, for example, with its relative selectivity for the cerebral vasculature Table 3 ; , was developed primarily for use in the management of patients with cerebral ischaemia [10]. Nisoldipine provides another example of a dihydropyridine-based antagonist which exhibits some selectivity within the vasculature in this instance for the coronary blood vessels [9]. Thus, enhanced tissue selectivity became an important hall-mark of the "second generation" calcium antagonists and created great interest and enthusiasm, but despite this improvement one other highly significant requirement was still lacking, as indeed it was in the "first generation" antagonists. This deficiency centred around their unfavourable pharmacokinetic profiles. Perhaps unfavourable is too harsh a word to apply to this deficiency, but in terms of their clinical use it was a major limiting factor. It was the search for a potent, vascular-selective calcium antagonist with a slow onset of action and a pharmacokinetic profile which would provide prolonged effective therapy without the need for multiple dosing throughout the day which led to the development of yet another calcium antagonist, amlodipine [13]. Not surprisingly the improved pharmacokinetic profile of amlodipine was accompanied by a significant reduction [15] in the intensity and occurrence of side-effects. Mic loop connecting repeats II and III 10, 23, 36 ; . The last event, ICa, L, occurs when the 11.1 has suffered additional changes that allow channel opening and calcium influx. The sequential relationship of the events resulting from DHPR activation would predict that any maneuvers that alter the conformational changes in 11.1 would have a similar effect on Q, calcium release, and ICa, L. In support of this hypothesis, many experiments have demonstrated that inhibition of the DHPR voltage sensor e.g., maintained depolarizations, DHPR antagonists, or changes in calcium levels ; reduces Q, calcium release, and ICa, L with a similar time course and magnitude 5, 12, 13, ; . However, other studies have revealed alternative effects on E-C coupling. For example, the voltage dependence of charge movement and calcium release or contraction properties ; is shifted in the hyperpolarizing direction without changes in the voltage dependence of ICa, L in the presence of perchlorate 6, 11, 19 ; or the R615C mutation in the RyR1 7 ; . In addition, the DHP nifedipine is also able to induce calcium release 39 ; and modify contractile activity 22 ; while blocking ICa, L. The differential effects of perchlorate and nifedipine on the events generated by DHPRs indicate that E-C coupling can be modulated at different steps, leading to the generation of charge movement, calcium release, and ICa, L. We have recently reported that the analgesic and antiepileptic drug gabapentin GBP ; causes a modest reduction of ICa, L in mouse skeletal myotubes 2 ; . In the present paper we have extended those studies and examined the effect of GBP on charge movement and calcium release in mouse myotubes. Interestingly, GBP binds to 2 1-subunits from brain and skeletal muscle with similar kinetics and high affinity kd 38 nM brain and 29 nM in skeletal muscle ; 17, 34 ; . Gee et al. 17 ; have also shown that, from 14 different tissues examined in the rat, the highest level of GBP-binding sites occurs in skeletal muscle. Therefore, this agent is unique because it binds to a subunit of the DHPR complex other than the 11.1, which is considered to be the voltage sensor. Our present studies demonstrate that GBP increases charge movement and decreases the rate.

Review: Good summary about party drugs. Includes a list of drugs with `street names' and how each is used, along with its main effects. Comes with suggestions of what the GP can do to help.
Time for ACTION: Re-evaluating the role of nifedipine in angina. Angina. 3 Wilcox RG, Hampton JR. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. Br Heart J 1981; 46: 498-502 Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991; 303: 1100-4 Broekman CPM, Haensel SM, Ven de Ven LLM, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 18: 325-31 Van de Ven LLM, Mouthaan BJ, Hoes MJ. Treatment of hyperventilation syndrome with bisoprolol: a placebo-controlled clinical trial. J Psychosom Res 1995; 39: 1007-13 Tseng C, Chiang F, Hsu K, Tseng Y, Hu W, Chen J, et al. Short-term efficacy and safety of bisoprolol in treatment of patients with mild-to-moderate hypertension - A two-center, double-blind study in Taiwan. Acta Cardiologica Sinica 1993; 9: 155-60 Davidov ME, Singh SP, Vlachakis ND, Blumenthal JB, Simon JS, Bryzinski JS, et al. Bisoprolol, a once-aday beta-blocking agent for patients with mild to moderate hypertension. Clin Cardiol 1994; 17: 263-268 Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. J Cardiol 1991; 68: 61-4 Williams RL, Goyle KK, Herman TS, Rofman BA, Ruoff GE, Hogan LB. Dose-dependent effects of betaxolol in hypertension: a double-blind multicenter study. J Clin Pharmacol 1992; 32: 360-7 Ameling EH, de Korte DF, Man in 't Veld AJ. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991; 18: 752-60 Salonen JT, Palminteri R. Comparison of two doses of betaxolol and placebo in hypertension: a randomised, double-blind cross-over trial. Eur J Clin Pharmacol 1982; 23: 491-4 Gudbjornsdottir S, Fowelin J, Elam M, Attvall S, Bengtsson BA, Marin P, et al. The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormome levels in hypertensive subjects. Eur J Clin Invest 1997; 27; 29-35 Groop L, Ttterman KJ, Harno K, Gordin A. Influence of beta-blocking drugs on glucose metabolism in hypertensive, non-diabetic patients. Acta Med Scand 1983; 213: 9-14 Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J Intern Med 1994; 235: 335-41 Jttel A, Baandrup S, Houtzagers J, Westergren G. The efficacy of low dose metoprolol CR ZOK in mild hypertension and in elderly patients with mild to moderate hypertension. J Clin Pharmacol 1990; 30 Suppl ; : S66-S71 Lepntalo MJA, Ttterman KJ. Lower limb haemodynamics during antihypertensive treatment with metoprolol and propranolol. Int Angiol 1985; 4: 225-8 MacMahon S, MacDonald GJ, Bernstein L, Andrews G, Blacket RB. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985; 1: 1233-6 Reybrouck T, Amery A, Fagard R, Jousten P, Lijnen P, Meulepas E. Beta-blockers: once or three times a day? BMJ 1978; 1: 1386-8 Vandongen R, Margetts B, Deklerk N, Beilin LJ, Rogers P. Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol. Br J Clin Pharmacol 1986; 21: 627-32 Trafford JAP, Latta D, Little PS, Parsley J, Ankier SI. A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension. Curr Med Res Opin 1989; 11: 550-6 Kimura S, DeQuattro V, Hernandez PH, Lee DD. Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension. J Cardiol 1988; 62: 751-4 Watson RDS, Stallard TJ, Littler WA. Comparison of once and twice daily administration of acebutolol in hypertension. Br J Clin Pharmacol 1980; 9: 209-12 Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JIS. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997; 11: 139-44 Himmelmann A, Hedner T, Ssnoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996; 51: 259-64 van Merode T, van Bortel L M, Smeets FA, Mooij JM, Bohm RO, Rahn KH, et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens 1989; 7 suppl 6 ; : S262-3 Glassock RJ, Weitzman RE, Bennett CM, Maxwell M, Hamilton B, Winer N, et al. Pindolol: effects on blood pressure and plasma renin activity. Heart J 1982; 104: 421-5 Hamilton BP, Hamilton J, Kirkendall WM. Pulmonary function in hypertensive patients treated with pindolol: a report of two studies. Heart J 1982; 104: 432-7 Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999; 45: 1170-7 Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. J Clin Psychopharmacol 1998; 18: 441-6 Pearson RM, Bulpitt CJ, Havard CWH. Biochemical and haematological changes induced by tienilic acid.

Addition of the drug 10 6 M ; while the cytosolic C EBP- pool was depleted Fig. 2d ; . GR translocation activation by amlodipine 10 8 M ; was confirmed by Western blot using 5 g of total protein per lane. Equal loading was controlled after transfer onto PVDF membranes by Ponceau staining. Amlodipine 10 8 M ; and nifedipinf 10 8 M ; induced translocation of the GR at 30 min for up to 3 However, the translocation induced by amlodipine 10 8 M ; was far more pronounced Fig. 3a ; . In contrast, verapamil 10 8 M ; failed to affect cellular compartmentalization of the GR data not shown ; . The shift of GR by amlodipine was demonstrated by EMSA during a similar time course using a DNA consensus sequence containing the GRE Fig. 3b ; . The time course of the amlodipine-induced functional activation of the GR was tested with a GRE oligonucleotide by EMSA and was similar to that observed by Western blot. The activation of C EBP- by amlodipine 10 6 M ; was demonstrated by EMSA using the same protein extracts used for GR activity, but in the presence of a CCAAT enhancer consensus oligonucleotide Fig. 3c ; . Binding of C EBP could be detected 3 h after addition of amlodipine 10 6 M ; , persisting until 6 h. Table 4. Comparison of the proposed methods with existing spectrophotometric methods for the estimation of nifedipine in pharmaceutical formulations and sumycin and nifedipine. TABLE 31 Standardised 28-day cost of devices and drug A ; Drug Device class Standardised 28-day cost , mean SD ; Low dose Beclometasone dipropionate Standard pMDI BA-pMDI DPI Standard pMDI DPI Nebuliser Standard pMDI DPI Standard pMDI DPI Nebuliser Standard pMDI BA-pMDI DPI Nebuliser Standard pMDI DPI Nebuliser 6.06 2.15 ; 7.06 2.90 ; 8.38 1.82 ; 6.39 1.51 ; 10.36 0.00 ; 30.42 7.67 ; 11.74 1.51 ; 11.36 3.35 ; 3.89 1.78 ; 16.07 0.00 ; 43.49 3.87 ; 2.36 8.16 ; 1.97 ; 3.39 ; 10.96 ; High dose 24.25 8.61 ; 28.24 11.60 ; 33.50 7.26 ; 25.56 6.05 ; 10.36 0.00 ; 121.68 30.66 ; 46.95 6.05 ; 45.43 13.39 ; 1.95 0.89 ; 16.07 0.00 ; 16.09 4.50 ; 2.36 3.97 ; 1.97 ; 1.40 ; 5.06. It is well known that rapid ascent increases the risk of decompression illness and evidence continues to gather on the safest ascent rates and optimum decompression profiles. Tables exist that attempt to minimise bubble formation as detected by Doppler ultrasound and these are useful for divers with unexplained decompression illness, or those found to have a patent foramen ovale but not wishing to undergo closure. A recent study of 28 recreational divers used Doppler scores of venous bubble formation to assess the safety of two ascent rates in open water conditions to 35 metres. They found a significantly higher bubble score using the Spencer scale and Kisman integrated severity score, KISS ; in divers surfacing to the decompression stop at 17 metres per minute, compared with the group surfacing at 9 metres per minute. Rapid uncontrolled ascents are a major cause of decompression illness in the UK and divers should already be aware of the risks involved. Dive computers are supposed to help control ascent rates but can be very sensitive to arm movement and posture. Divers may ignore alarm signals during the ascent for this reason and should be advised of the need to maintain a slow controlled ascent to minimise their risk. For more information: Carturan D, Boussuges A, Molenat F, Burnet H, Fondarai J, Gardette B. Int J Sports Med 2000; 21 7 ; : 459-62 and risedronate. Could this be a side effect of the heart medications or could it be another condition. Table 2. Characteristics of the patients with malignant B-cell lymphoma who developed PCP during treatment with CHOEP-14 and rituximab.

Nifedipine dosage Of the dihydropyridine nifedipine; however, the translocation of GR by amlodipine was more efficacious, which could be explained by stereochemical differences between the two CCBs. It is noteworthy that the effect of the two dihydropyridines could not be mimicked by verapamil, which strengthens the argument for a specific antiproliferative efficacy of dihydropyridines independent of the role of intracellular calcium. In conclusion, we suggest that the antiproliferative action of amlodipine and other dihydropyridines is mediated by the activation of p21 Waf1 Cip1 ; via GR and C EBP. Physical examination and clinical laboratory tests. Patients selected for treatment with PDE5 inhibitors should be instructed in the proper use of these drugs and about possible interactions that may reduce efficacy or increase the risk for AEs. They also should be informed about potential side effects of therapy and when they are likely to occur. Initial dosing with PDE5 inhibitors should be modified as necessary for patients in special populations. Patients started on regimens of PDE5 inhibitors should also be followed closely to determine whether dosing adjustments are required. While all PDE5 inhibitors have the same mechanism of action, these drugs do differ in their potency for inhibiting PDE5 and their selectivity for this enzyme versus other PDE families. While it is not clear how these differences affect safety and efficacy, clinical trial results support the view that patients may easily switch from one drug in this class to another, for example, nifedipine er drug. Patient who was treated with Nifedipine for 15 months and did not have any other drug was prepared from the areas of 2 1 and 1-5. The histological samples were immediately fixed in 10% formalin and stained with hematoxilyne and eosine. Infiltration of inflammatory cells, especially mast cells was confirmed by special staining. Comparison of the gingivitis prevalence between study and control groups was performed using 2 test. Also, 2 test was used to compare the disease type in Nifedipine group between patients with enlargement. Age, drug consumption period, average dosage of drug and PI was compared using t- student test between patients with and without gingival hyperplasia. Results: In the study group, 17% was affected with gingival hyperplasia 52.94% female and 47.05% male ; . Gingival hyperplasia was not observed in any of the control patients. The highest prevalence of gingival enlargement was in the 4th decade of life. The severity of gingivitis and gingival index level was greater in Nifedipine study ; group as compared to the control group, but the difference wasn't statistically significant P 0.05 ; Tables II ; . Plaque index of study and control groups has been showed in Table III. In this study, there was a statistically significant relationship between plaque index PI ; and drug dosage with gingival changes. Hyperplasia was not related to factors such as: age, type of disease, and the duration of Nifedipine consumption. Clinical observation in patients with gingival overgrowth, showed a lobular or nodular enlargement of interdental papilla in the anterior region. Gingival consistency was spongy congested, and hemorrhagic. These changes were limited to the attached gingiva. Generally, gingival overgrowth was more obvious in the anterior and reminyl!

Where to buy Nifedipine Axcan submitted an snds in canada during the first quarter of fiscal 200 the company received, and responded to, questions in a non-approvable letter from health canada during the third quarter of fiscal 200 axcan anticipates a response from health canada in the first half of fiscal 200 axcan in-licensed from gentium spa “ gentium” , an italian company, exclusive rights to develop and market in north america a new mesalamine rectal gel to be developed for the treatment of distal ulcerative colitis. Rarely, patients, usually receiving a beta blocker, have developed well tolerated across beginning nifedipine. Response of the collagenase promoter in F9 cells to increasing amounts of Jun, Fos, or their combination, in the absence of ER. Transfections included up to 10 Jun or Fos expression vector and were normalized for DNA content. To confirm that AP-1 proteins were absolutely required for the AP-1 -directed ER pathway, we turned to F9 cells, which have only low levels of endogenous AP-1 activity 28, 29 ; . Transfection of an expression vector for ER into these cells did not support hormone activation of the collagenase promoter Fig. 4B; see also Table l ; , whereas it gave strong estrogen activation at an ERE not shown ; . Cotransfection of ER with Jun Fos restored induction by both estrogen and antiestrogens in F9 cells, albeit at lower levels than that seen in HeLa cells. In addition, there was some activation by unliganded ER. This effect is similar to activation by unliganded ER that is obtained in HeLa cells Fig. 2A ; and to one that we have previously observed with the thyroid hormone receptor 30 ; . Thus, the inability of F9 cells to allow a hormone response at the collagenase promoter can be overcome with AP-1 supplied by transfection. We conclude that hormone effects at the AP-1 site require AP-1 protein. However, the dramatic difference between the hormone response of HeLa and F9 cells when both are supplied with Jun and Fos indicates that other.

Clin. Assoc. Prof. Amanda Oakley, Dept of Dermatology, Health Waikato Wairakei, June 2005 This presentation Clinical features of atopic dermatitis Treatment of atopic dermatitis Role of calcineurin inhibitors Acknowledgements: Some charts & images were given to me by Novartis Declarations: I have been a Principal Investigator for an Elidel trial I have been on the Elidel Advisory Board Novartis has been a sponsor of DermNetNZ Diagnosis of atopic dermatitis Acute, subacute, chronic skin disorder Onset usually in infancy Characteristic age-dependent distribution Marked pruritus Scratching leads to lichenification Associated with personal or family history of AD, asthma, allergic rhinitis Atopic dermatitis in infants Onset after 3 months of age 60% present before 12 months A further 30% before 5 years Dermatitis most marked on face esp. cheeks & extensor surfaces of limbs May result in red skin and tiny vesicles all over Scaling, exudation, fissures below ears Atopic dermatitis in children Symmetrical eruption affecting antecubital & popliteal fossae, neck Acute dermatitis: erythematous papules, plaques, erosions, pustules, crusts & excoriations Chronic dermatitis: lichenification, broken-off hairs, less inflammation In dark skins: Follicular accentuation Postinflammatory hyperpigmentation Postinflammatory hypopigmentation.